1235543-75-5

Upstream product

• 1235543-74-4 (2Z)-7-(tert-butyldiphenylsilyloxy)hept-2-en-1-ol 
• 1235543-73-3 tert-butyldiphenyl ((7-((tetrahydro-2H-pyran-2-yl)oxy)hept-5-yn-1-yl)oxy)silane 
• 125010-58-4 (4-bromobutoxy)(tert-butyl)diphenylsilane 
• 125010-59-5 7-(tert-butyldiphenylsilyloxy)-hept-2-yn-1-ol 

Downstream Products

• 1235543-76-6 (2S,3S)-3-[4-(tert-butyldiphenylsilanyloxy)butyl]oxirane-2-carbaldehyde 
• 1235543-77-7 (3R,4S)-tert-butyldiphenyl-[4-(3-vinyloxiranyl)butoxy]silane 

Relevant academic research and scientific papers

17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues

17(R),18(S)-Epoxyeicosatetraenoic acid [17(R),18(S)-EETeTr], a cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid (EPA), exerts negative chronotropic effects and protects neonatal rat cardiomyocytes against Ca 2+-overload with EC50 ≈ 1-2 nM. Structure-activity studies revealed that a cis-Δ11,12- or Δ14,15- olefin and a 17(R),18(S)-epoxide are minimal structural elements for antiarrhythmic activity whereas antagonist activity was often associated with the combination of a Δ14,15-olefin and a 17(S),18(R)-epoxide. Compared with natural material, the agonist and antagonist analogues are chemically and metabolically more robust and several show promise as templates for future development of clinical candidates.

Novel eicosanoid derivatives

The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.